Viewing Study NCT02122003

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:11 PM
Ignite Modification Date: 2026-02-28 @ 8:47 PM
Study NCT ID: NCT02122003
Status: TERMINATED
Last Update Posted: 2017-11-22
First Post: 2014-04-06
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Second Line Sorafenib After Pazopanib in Patients With RCC
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Renal Cell Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None sorafenib View
None pazopanib View
None cross-resistance View
None TKI View
None mRCC View